Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM057200-008
Application #
2591816
Study Section
Project Start
1994-12-01
Project End
1999-11-30
Budget Start
1997-06-16
Budget End
1997-05-31
Support Year
Fiscal Year
1997
Total Cost
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Reid, Joel M; Squillace, David P; Ames, Matthew M (2003) Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol 51:483-7
Reid, Joel M; Kuffel, Mary J; Ruben, Stacie L et al. (2002) Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 8:2952-62
Budihardjo, I I; Boerner, S A; Eckdahl, S et al. (2000) Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. Mol Pharmacol 57:529-38
Walker, D L; Reid, J M; Svingen, P A et al. (1999) Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol 58:1057-66
Pitot, H C; McElroy Jr, E A; Reid, J M et al. (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5:525-31
Budihardjo, I I; Walker, D L; Svingen, P A et al. (1998) 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 4:117-30